CERP PATENT FILED//Files Patent on Algae Bio-Content

New Post Public Reply Private Reply Replies (0) Message Board

Mar 21, 2013 at 2:25 PM

CERP >>PATENT FILED//Files Patent on Algae Bio-Content Polymers

2013-03-19 08:00 ET - News Release

EL SEGUNDO, Calif., March 19, 2013 (GLOBE NEWSWIRE) -- Cereplast, Inc. (OTCQB:CERP) (the "Company"), a leading manufacturer of proprietary biobased, compostable and sustainable bioplastics, today announced that the Company filed a patent application on March 15, 2013 with the United States Patent and Trademark Office (USPTO) for algae bio-content polymers.

Cereplast's new patent filing falls in line with their overall intellectual property strategy and specifically protects its innovations on Algae related material. This patent application is the result of several years of formulation and process development by the Cereplast research and development team. The Company first introduced the concept of bioplastics made with algae in 2009, commercialized Biopropylene® 109D in late 2012 and incorporated a wholly owned subsidiary, Algaeplast™, Inc., in early 2013.

Algaeplast will take over the development and manufacture of algae-based bioplastics to transform a range of low-cost algae into high-value bioplastic resins and renewable biofuels. The patent application was filed by Cereplast, but the use of the patent will be assigned to Algaeplast.

Cereplast Chairman and CEO, Mr. Frederic Scheer, stated, "This patent is one of many steps on our journey of developing this new category of plastic. We see a significant future ahead for the estimated over $100 billion algae biofuels and bioplastics industry, and we are firmly committed to protecting the intellectual property of the Company as we further our work. Considering there is a lack of algae bioplastic patents today, we strongly believe that our experience and research and development capability has allowed us to foresee the future of renewable plastics and carry out this valuable technology. We also believe that our vision is starting to take shape with algae being on the verge of large commercial production for biofuels and bioplastic applications. Large companies in the airline industry and others are following the progress of numerous companies ready to commercially offer algae as a viable alternative to petroleum, both for fuel and chemicals. Algaeplast wants to be at the forefront of this new fuel and chemical revolution."

About Cereplast, Inc.

Cereplast, Inc. (OTCQB:CERP) designs and manufactures proprietary biobased, sustainable bioplastics which are used as substitutes for traditional plastics in all major converting processes - such as injection molding, thermoforming, blow molding and extrusions - at a pricing structure that is competitive with traditional plastics. On the cutting-edge of biobased plastic material development, Cereplast now offers resins to meet a variety of customer demands. Cereplast Compostables® resins are ideally suited for single-use applications where high biobased content and compostability are advantageous, especially in the food service industry. Cereplast Sustainables® resins combine high biobased content with the durability and endurance of traditional plastic, making them ideal for applications in industries such as automotive, consumer electronics and packaging. Learn more at www.cereplast.com. You may also visit the Cereplast social networking pages at Facebook.com/Cereplast, Twitter.com/Cereplast and Youtube.com/Cereplastinc.

The Cereplast, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9567

CONTACT: Cereplast, Inc.
Public Relations
Nicole Robertson
(310) 615-1900 x154
nrobertson@cereplast.com

Investor Relations:
Alliance Advisors, LLC
Alan Sheinwald
914-669-0222
asheinwald@allianceadvisors.net

Valter Pinto
914-669-0222 x201
valter@allianceadvisors.net
www.AllianceAdvisors.net

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...